TeVido BioDevices featured in:  “Bioprinting: the future of organ transplant”

TeVido BioDevices featured in:  “Bioprinting: the future of organ transplant”


At the end of June, Biolife4D announced it had successfully 3D printed human cardiac tissue in patch form. The cardiac patch was printed in a number of days, rather than the timeframe of six to eight months predicted in scientific literature. Innovations such as Biolife4D’s are part of the next wave of medical advancement that will produce novel patient therapies: bioprinting.

Bioprinting is a form of 3D printing that employs living cells, or “bioink,” as the printing material. Generally, bioink is deposited onto a gel in layers, resulting in a 3D-printed biological structure. In addition to Biolife4D, other companies such as Organovo and TeVido BioDevices are innovating with proprietary bioprinting technologies. Biolife4D’s technique utilises a patient’s own white blood cells, which are reprogrammed into induced pluripotent stem cells and then cardiac cells. Similarly, TeVido is developing nipple reconstruction implants for breast cancer survivors by employing a patient’s own skin cells in a proprietary process. Organovo creates functional 3D human tissue products using the company’s proprietary NovoGen Bioprinters and bioink technology, which minimise the use of biomaterials other than human cells and allow dense cellularity in the resulting tissue. Organovo’s first program is targeting rare liver disease.

Bioprinted tissue holds a wealth of promise for the future of healthcare. Tissue can be utilised for drug development and safety, as well as other medical research efforts. In the future, the aim is to create replacement organs for patients in need of a transplant. According to UNOS, nearly 15,000 patients in the US are currently on the organ transplant waiting list and 20 patients die each day, on average, while waiting for a transplant.

Read more:  https://www.medicaldevice-network.com/comment/bioprinting-future-organ-transplant/

Bioprinting: the future of organ transplant